-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Benzinga·09/22/2026 12:38:38
Listen to the news
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.